{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:06:12Z","timestamp":1791518772264,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Gout is one of the most prevalent forms of arthritis that is usually accompanied by other comorbidities. For this reason, multiple drugs are routinely prescribed for gout patients, which may affect the clinical course outcomes, and increase the risk of drug-drug interactions. This work presents a novel, simple, and sensitive high performance liquid chromatography (HPLC) method for the simultaneous determination of lesinurad (LES) and other co-administered drugs that are subject to potential pharmacokinetic interactions such as etoricoxib (ETC), eplerenone (EPL), and amiodarone (AMD) in rat plasma. Moreover, a pharmacokinetic study was conducted by co-administration of LES and ETC to rats to assess any possible alteration in their pharmacokinetic profiles and the obtained samples were analyzed using the developed method. Chromatographic separation was achieved using a gradient elution of a mobile phase consisting of acetonitrile and potassium dihydrogen orthophosphate buffer, pH 4.2 on a Zorbax Eclipse Plus C18 (4.6\u2009\u00d7\u2009250\u00a0mm, 5\u00a0\u03bcm particle size) column. The developed method exhibits adequate sensitivity with a LLOQ of 100 ng\/mL and was successfully validated as per the FDA bioanalytical guidelines and was found to be linear over the range from 100 to 50,000 ng\/mL for all the selected drugs. The results of the pharmacokinetic study showed an increase in the area under the curve (AUC) of each of the two drugs (LES and ETC) following the repeated administration of the other. This raises concerns of the possible renal injurious effect of ETC when co-prescribed with LES. Moreover, this work uncovers the necessity for therapeutic dose adjustment or increased clinical vigilance for side effects and\/or lack of efficacy upon concomitant administration of the selected drugs to gout patients.<\/jats:p>","DOI":"10.1038\/s41598-025-93680-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:41:23Z","timestamp":1743774083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous determination of lesinurad and co-administered drugs used in management of gout comorbidities to uncover potential pharmacokinetic interaction in rat plasma"],"prefix":"10.1038","volume":"15","author":[{"given":"Hadeel A.","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman I.","family":"El-Kimary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Elrewiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed F.","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek S.","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"93680_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","volume":"14","author":"RL Wortmann","year":"2002","unstructured":"Wortmann, R. L. Gout and hyperuricemia. Curr. Opin. Rheumatol. 14, 281\u2013286 (2002).","journal-title":"Curr. Opin. Rheumatol."},{"key":"93680_CR2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/berh.2000.0087","volume":"14","author":"NW McGill","year":"2000","unstructured":"McGill, N. W. Gout and other crystal-associated arthropathies. Best Pract. Res. Clin. Rheumatol. 14, 445\u2013460 (2000).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"93680_CR3","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: The national health and nutrition examination survey 2007\u20132008. Arthritis Rheum. 63, 3136\u20133141 (2011).","journal-title":"Arthritis Rheum."},{"key":"93680_CR4","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee, E., Michet, C. J., Crowson, C. S., O\u2019Fallon, W. M. & Gabriel, S. E. Epidemiology of gout: Is the incidence rising?. J. Rheumatol. 29, 2403\u20132406 (2002).","journal-title":"J. Rheumatol."},{"key":"93680_CR5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi, M. M. et al. The rising incidence of gout and the increasing burden of comorbidities: A population-based study over 20 years. J. Rheumatol. 45, 574\u2013579 (2018).","journal-title":"J. Rheumatol."},{"key":"93680_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/rheumatology\/kes211","volume":"52","author":"LK Stamp","year":"2013","unstructured":"Stamp, L. K. & Chapman, P. T. Gout and its comorbidities: Implications for therapy. Rheumatology (Oxford) 52, 34\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/kes211 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"93680_CR7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2125.2012.04264.x","volume":"74","author":"R Ferner","year":"2012","unstructured":"Ferner, R. Handbook of drug interactions: A clinical and forensic guide. Br. J. Clin. Pharmacol. 74, 893 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"93680_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin, T. & Richette, P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 15, 123\u2013123. https:\/\/doi.org\/10.1186\/s12916-017-0890-9 (2017).","journal-title":"BMC Med."},{"key":"93680_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40744-019-0143-9","volume":"6","author":"F Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz, F. et al. Reassessing the safety profile of lesinurad in combination with xanthine oxidase inhibitor therapy. Rheumatol. Therapy 6, 101\u2013108 (2019).","journal-title":"Rheumatol. Therapy"},{"key":"93680_CR10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpdd.323","volume":"6","author":"Z Shen","year":"2017","unstructured":"Shen, Z. et al. Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout treatment. Clin. Pharmacol. Drug Dev. 6, 377\u2013387 (2017).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"93680_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","volume":"18","author":"JN Miner","year":"2016","unstructured":"Miner, J. N. et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res. Ther. 18, 214. https:\/\/doi.org\/10.1186\/s13075-016-1107-x (2016).","journal-title":"Arthritis Res. Ther."},{"key":"93680_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ckj\/sfx036","volume":"10","author":"MD Sanchez-Ni\u00f1o","year":"2017","unstructured":"Sanchez-Ni\u00f1o, M. D. et al. Lesinurad: What the nephrologist should know. Clin. Kidney J. 10, 679\u2013687. https:\/\/doi.org\/10.1093\/ckj\/sfx036 (2017).","journal-title":"Clin. Kidney J."},{"key":"93680_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40261-016-0386-y","volume":"36","author":"Z Shen","year":"2016","unstructured":"Shen, Z. et al. In vitro and in vivo interaction studies between lesinurad, a selective urate reabsorption inhibitor, and major liver or kidney transporters. Clin. Drug Investig. 36, 443\u2013452. https:\/\/doi.org\/10.1007\/s40261-016-0386-y (2016).","journal-title":"Clin. Drug Investig."},{"key":"93680_CR14","doi-asserted-by":"publisher","first-page":"010120","DOI":"10.1002\/14651858.CD010120.pub3","volume":"12","author":"CM van Durme","year":"2021","unstructured":"van Durme, C. M. et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst. Rev. 12, 010120. https:\/\/doi.org\/10.1002\/14651858.CD010120.pub3 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"93680_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00003088-200847110-00002","volume":"47","author":"JK Takemoto","year":"2008","unstructured":"Takemoto, J. K., Reynolds, J. K., Remsberg, C. M., Vega-Villa, K. R. & Davies, N. M. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin. Pharmacokinet. 47, 703\u2013720. https:\/\/doi.org\/10.2165\/00003088-200847110-00002 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"93680_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2174\/187231211795305285","volume":"5","author":"H Honjo","year":"2011","unstructured":"Honjo, H., Uwai, Y. & Iwamoto, K. Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3). Drug. Metab. Lett. 5, 140\u2013137. https:\/\/doi.org\/10.2174\/187231211795305285 (2011).","journal-title":"Drug. Metab. Lett."},{"key":"93680_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpdd.324","volume":"6","author":"M Gillen","year":"2017","unstructured":"Gillen, M. et al. Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and CYP enzyme substrates sildenafil, amlodipine, tolbutamide, and repaglinide. Clin. Pharmacol. Drug Dev. 6, 363\u2013376. https:\/\/doi.org\/10.1002\/cpdd.324 (2017).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"93680_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00296-021-04876-6","volume":"41","author":"P Cox","year":"2021","unstructured":"Cox, P., Gupta, S., Zhao, S. S. & Hughes, D. M. The incidence and prevalence of cardiovascular diseases in gout: A systematic review and meta-analysis. Rheumatol. Int. 41, 1209\u20131219. https:\/\/doi.org\/10.1007\/s00296-021-04876-6 (2021).","journal-title":"Rheumatol. Int."},{"key":"93680_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/chromsci\/bmy010","volume":"56","author":"KAM Attia","year":"2018","unstructured":"Attia, K. A. M., El-Abasawi, N. M., El-Olemy, A. & Abdelazim, A. H. Validated stability indicating high performance liquid chromatographic determination of lesinurad. J. Chromatogr. Sci. 56, 358\u2013366. https:\/\/doi.org\/10.1093\/chromsci\/bmy010 (2018).","journal-title":"J. Chromatogr. Sci."},{"key":"93680_CR20","unstructured":"Sravanthi, T. & Madhavi, N. Chromatographic determination of allopurinol and lesinurad simultaneously in raw and tablet forms. Drug Invention Today 13 (2020)."},{"key":"93680_CR21","unstructured":"Dastiagiriamma, D., Kistayya, C., Sowjanya, H. M., & Hemalatha, K. Simultaneous estimation of lesinurad and allopurinol by using reverse phase high performance liquid chromatography in API and marketed formulation.\u00a0Int. J. Med. Pharm. Sci.,\u00a03 (2018)."},{"key":"93680_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2020.105199","volume":"158","author":"EI El-Kimary","year":"2020","unstructured":"El-Kimary, E. I., Khalil, H. A., Belal, T. S. & El-Yazbi, A. F. Green stability-indicating capillary electrophoretic method for simultaneous determination of Lesinurad and Allopurinol in tablet dosage form: Degradation kinetics investigation. Microchem. J. 158, 105199. https:\/\/doi.org\/10.1016\/j.microc.2020.105199 (2020).","journal-title":"Microchem. J."},{"key":"93680_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.119106","volume":"247","author":"AA Mohamed","year":"2021","unstructured":"Mohamed, A. A. et al. Spectrophotometric determination of lesinurad and allopurinol in recently approved FDA pharmaceutical preparation. Spectrochimica Acta Part A: Mol. Biomol. Spectr. 247, 119106 (2021).","journal-title":"Spectrochimica Acta Part A: Mol. Biomol. Spectr."},{"key":"93680_CR24","volume":"285","author":"AH Abdelazim","year":"2023","unstructured":"Abdelazim, A. H., Abourehab, M. A., Abd Elhalim, L. M., Almrasy, A. A. & Ramzy, S. Different spectrophotometric methods for simultaneous determination of lesinurad and allopurinol in the new FDA approved pharmaceutical preparation; additional greenness evaluation. Spectrochimica Acta Part A: Mol. Biomol. Spectr. 285, 121868 (2023).","journal-title":"Spectrochimica Acta Part A: Mol. Biomol. Spectr."},{"key":"93680_CR25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/22297928.2018.1498388","volume":"8","author":"KA Attia","year":"2018","unstructured":"Attia, K. A., El-Abasawi, N. M., El-Olemy, A. & Abdelazim, A. H. Different mathematical spectrophotometric methods for determination of lesinurad in the presence of its oxidative degradation product. Anal. Chem. Lett. 8, 747\u2013756 (2018).","journal-title":"Anal. Chem. Lett."},{"key":"93680_CR26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1039\/C7NJ03809G","volume":"42","author":"K Attia","year":"2018","unstructured":"Attia, K., El-Abassawi, N., El-Olemy, A. & Abdelazim, A. Second derivative spectrophotometric and synchronous spectrofluorometric determination of lesinurad in the presence of its oxidative degradation product. New J. Chem. 42, 995\u20131002 (2018).","journal-title":"New J. Chem."},{"key":"93680_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213786","volume":"14","author":"M Iqbal","year":"2019","unstructured":"Iqbal, M., Ezzeldin, E., Herqash, R. N. & Alam, O. Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. PLoS One 14, e0213786. https:\/\/doi.org\/10.1371\/journal.pone.0213786 (2019).","journal-title":"PLoS One"},{"key":"93680_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.118871","volume":"244","author":"KA Attia","year":"2021","unstructured":"Attia, K. A. et al. Application of different spectrofluorimetric methods for determination of lesinurad and allopurinol in pharmaceutical preparation and human plasma. Spectrochimica Acta Part A: Mol. Biomol. Spectr. 244, 118871 (2021).","journal-title":"Spectrochimica Acta Part A: Mol. Biomol. Spectr."},{"key":"93680_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.119239","volume":"248","author":"G Magdy","year":"2021","unstructured":"Magdy, G., Belal, F. F., Abdel-Megied, A. M. & Hakiem, A. F. A. Micelle-enhanced conventional and synchronous spectrofluorimetric methods for the simultaneous determination of lesinurad and febuxostat: Application to human plasma. Spectrochimica Acta Part A: Mol. Biomol. Spectr. 248, 119239 (2021).","journal-title":"Spectrochimica Acta Part A: Mol. Biomol. Spectr."},{"key":"93680_CR30","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/jssc.202100016","volume":"44","author":"G Magdy","year":"2021","unstructured":"Magdy, G., Abdel Hakiem, A. F., Belal, F. & Abdel-Megied, A. M. A novel quality by design approach for development and validation of a green reversed-phase HPLC method with fluorescence detection for the simultaneous determination of lesinurad, febuxostat, and diflunisal: Application to human plasma. J. Separation Sci. 44, 2177\u20132188 (2021).","journal-title":"J. Separation Sci."},{"key":"93680_CR31","unstructured":"Guidance for Industry: Bioanalytical Method Validation, U. D. O. H. A. H. S., Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), FDA, Rockville, MD, USA (2013)."},{"key":"93680_CR32","unstructured":"Food & Administration, D. M10 bioanalytical method validation and study sample analysis. Guidance for Industry (2022)."},{"key":"93680_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4155\/bio-2018-0219","volume":"11","author":"FA El-Yazbi","year":"2019","unstructured":"El-Yazbi, F. A. et al. A novel HPLC-DAD method for simultaneous determination of febuxostat and diclofenac in biological samples: Pharmacokinetic outcomes. Bioanalysis 11, 41\u201354. https:\/\/doi.org\/10.4155\/bio-2018-0219 (2019).","journal-title":"Bioanalysis"},{"key":"93680_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2021.105964","volume":"164","author":"AF El-Yazbi","year":"2021","unstructured":"El-Yazbi, A. F., Khalifa, Y., Elkhatib, M. A. W. & El-Yazbi, A. F. Green analytical method for the determination of sofosbuvir, ledipasvir, ribavirin and complex silymarin flavonoids simultaneously in biological fluids. Microchem. J. 164, 105964. https:\/\/doi.org\/10.1016\/j.microc.2021.105964 (2021).","journal-title":"Microchem. J."},{"key":"93680_CR35","doi-asserted-by":"publisher","first-page":"117415","DOI":"10.1016\/j.ejmech.2025.117415","volume":"289","author":"MS El-Shoukrofy","year":"2025","unstructured":"El-Shoukrofy, M. S. et al. Novel thiazolones for the simultaneous modulation of PPAR\u03b3, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation. Eur. J. Med. Chem. 289, 117415. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117415 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"93680_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3892\/br.2017.942","volume":"7","author":"J Yuan","year":"2017","unstructured":"Yuan, J., Ma, H., Cen, N., Zhou, A. & Tao, H. A pharmacokinetic study of diclofenac sodium in rats. Biomed. Rep. 7, 179\u2013182. https:\/\/doi.org\/10.3892\/br.2017.942 (2017).","journal-title":"Biomed. Rep."},{"key":"93680_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.827668","volume":"13","author":"W Cheng","year":"2022","unstructured":"Cheng, W. et al. Pharmacokinetics, tissue distribution, and excretion characteristics of a radix polygoni multiflori extract in rats. Front. Pharmacol. 13, 827668. https:\/\/doi.org\/10.3389\/fphar.2022.827668 (2022).","journal-title":"Front. Pharmacol."},{"key":"93680_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.talo.2021.100052","volume":"4","author":"WD Eure","year":"2021","unstructured":"Eure, W. D., Grossman, R. G., Horner, P. J. & Chow, D. S. L. LC-MS\/MS assay of riluzole and etoricoxib in rat plasma and brain tissue with applications for sampling and evaluation in pre-clinical rat model of traumatic brain injury. Talanta Open 4, 100052. https:\/\/doi.org\/10.1016\/j.talo.2021.100052 (2021).","journal-title":"Talanta Open"},{"key":"93680_CR39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00011-008-8029-2","volume":"57","author":"E Bressan","year":"2008","unstructured":"Bressan, E. & Tonussi, C. R. Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis. Inflamm. Res. 57, 586\u2013592. https:\/\/doi.org\/10.1007\/s00011-008-8029-2 (2008).","journal-title":"Inflamm. Res."},{"key":"93680_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/bdd.2510080106","volume":"8","author":"P Macheras","year":"1987","unstructured":"Macheras, P. Method of residuals: estimation of absorption and elimination rate constants having comparable values. Biopharm. Drug Dispos. 8, 47\u201356. https:\/\/doi.org\/10.1002\/bdd.2510080106 (1987).","journal-title":"Biopharm. Drug Dispos."},{"key":"93680_CR41","unstructured":"The United States Pharmacopeia, R. E. T. N. F., 28th Edition. (United States Pharmacopeial Convention, Inc., Rockville, USA, 2024)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93680-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:58:40Z","timestamp":1744286320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93680-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93680"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93680-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11238"}}